{"doc_id": "si-2023-0284-reg-1", "parent_doc_id": "si-2023-0284", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 284 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No. 4) Regulations 2023. \n\n(2) The collective citation “the Medicinal Products (Prescription and Control \n\nof Supply) Regulations 2003 to 2023” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 4) regulation 2023 (2) collective citation medicinal product (prescription control supply) regulation 2003 2023 includes regulation", "start_char": 620, "end_char": 910, "source_path": "downloads\\2023\\2023_0284.pdf", "extraction_method": "pdfminer", "checksum": "sha256:02c1a54113e4146bf08f47e20d3abe4a8298a95acbe5cf4c1edc8bec30c774a8", "cross_refs": []}
{"doc_id": "si-2023-0284-reg-2", "parent_doc_id": "si-2023-0284", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 284 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription and Control \nof Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2020” means the Medicinal Products (Prescription and Control \nof Supply) (Amendment) Regulations 2020 (S.I. No. 98 of 2020); \n\n“Regulations of 2021” means the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 10) Regulations 2021 (S.I. No. 511 of 2021); \n\n“Regulations of 2023” means the Medicinal Products (Prescription and Control \nof Supply (Amendment) (No. 2) Regulations 2023 (S.I. No. 105 of 2023).", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2020 mean medicinal product (prescription control supply) (amendment) regulation 2020 (s.i no 98 2020) regulation 2021 mean medicinal product (prescription control supply) (amendment) (no 10) regulation 2021 (s.i no 511 2021) regulation 2023 mean medicinal product (prescription control supply (amendment) (no 2) regulation 2023 (s.i no 105 2023)", "start_char": 910, "end_char": 1520, "source_path": "downloads\\2023\\2023_0284.pdf", "extraction_method": "pdfminer", "checksum": "sha256:02c1a54113e4146bf08f47e20d3abe4a8298a95acbe5cf4c1edc8bec30c774a8", "cross_refs": []}
{"doc_id": "si-2023-0284-reg-3", "parent_doc_id": "si-2023-0284", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 284 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "3. Regulation 4(1) (as amended by Regulation 3(a) of the Medicinal", "text_raw": "3. Regulation 4(1) (as amended by Regulation 3(a) of the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 3) Regulations \n2023 (S.I. No. 238 of 2023)) of the Principal Regulations is amended by \nsubstituting for the definition of “Covid-19 emergency” the following definition: \n\n“‘Covid-19 situation’ means the situation resulting from the spread in the \nState of the disease caused by infection with the virus SARS-CoV-2, being \na disease specified as an infectious disease in accordance with Regulation \n6 of, and the Schedule to, the Infectious Diseases Regulations 1981 (S.I. \nNo. 390 of 1981), or any variant of the disease so specified as an infectious \ndisease in those Regulations;”", "text_norm": "3 regulation 4(1) (as amended regulation 3(a) medicinal product (prescription control supply) (amendment) (no 3) regulation 2023 (s.i no 238 2023)) principal regulation amended substituting definition covid-19 emergency following definition covid-19 situation mean situation resulting spread state disease caused infection virus sars-cov-2 disease specified infectious disease accordance regulation 6 schedule infectious disease regulation 1981 (s.i no 390 1981) variant disease specified infectious disease regulation", "start_char": 1520, "end_char": 2238, "source_path": "downloads\\2023\\2023_0284.pdf", "extraction_method": "pdfminer", "checksum": "sha256:02c1a54113e4146bf08f47e20d3abe4a8298a95acbe5cf4c1edc8bec30c774a8", "cross_refs": []}
{"doc_id": "si-2023-0284-reg-4", "parent_doc_id": "si-2023-0284", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 284 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "4. Regulation 4F (as amended by Regulation 3 of the Regulations of 2021)", "text_raw": "4. Regulation 4F (as amended by Regulation 3 of the Regulations of 2021) \n\nof the Principal Regulations is amended— \n\n(a) \n\nby substituting for the heading the following: \n\n“Supply and administration of certain medicinal products by \nhealth professions in context of Covid-19 situation”, and \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 6th June, 2023. \n\n \n \n \n \n \n \n \n\f[284] 3 \n\n(b) \n\nin paragraph (a), by substituting “Covid-19 situation” for “Covid19 emergency”.", "text_norm": "4 regulation 4f (as amended regulation 3 regulation 2021) principal regulation amended-- (a) substituting heading following supply administration certain medicinal product health profession context covid-19 situation notice making statutory instrument published iris oifigiuil 6th june 2023 284 3 (b) paragraph (a) substituting covid-19 situation covid19 emergency", "start_char": 2238, "end_char": 2751, "source_path": "downloads\\2023\\2023_0284.pdf", "extraction_method": "pdfminer", "checksum": "sha256:02c1a54113e4146bf08f47e20d3abe4a8298a95acbe5cf4c1edc8bec30c774a8", "cross_refs": []}
{"doc_id": "si-2023-0284-reg-5", "parent_doc_id": "si-2023-0284", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 284 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "5. Regulation 4G (as amended by Regulation 4 of the Regulations of 2021)", "text_raw": "5. Regulation 4G (as amended by Regulation 4 of the Regulations of 2021) \n\nof the Principal Regulations is amended— \n\n(a) \n\nby substituting for the heading the following: \n\n“Administration of certain medicinal products by students in \nhealth professions in context of Covid-19 situation”, and \n\n(b) \n\nin paragraph (a), by substituting “Covid-19 situation” for “Covid19 emergency”.", "text_norm": "5 regulation 4g (as amended regulation 4 regulation 2021) principal regulation amended-- (a) substituting heading following administration certain medicinal product student health profession context covid-19 situation (b) paragraph (a) substituting covid-19 situation covid19 emergency", "start_char": 2751, "end_char": 3134, "source_path": "downloads\\2023\\2023_0284.pdf", "extraction_method": "pdfminer", "checksum": "sha256:02c1a54113e4146bf08f47e20d3abe4a8298a95acbe5cf4c1edc8bec30c774a8", "cross_refs": []}
{"doc_id": "si-2023-0284-reg-6", "parent_doc_id": "si-2023-0284", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 284 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "6. Regulation 7(2A) (inserted by Regulation 4 of the Regulations of 2020)", "text_raw": "6. Regulation 7(2A) (inserted by Regulation 4 of the Regulations of 2020) \nof the Principal Regulations is amended by substituting “Covid-19 situation” for \n“Covid-19 emergency” in both places it occurs.", "text_norm": "6 regulation 7(2a) (inserted regulation 4 regulation 2020) principal regulation amended substituting covid-19 situation covid-19 emergency place occurs", "start_char": 3134, "end_char": 3340, "source_path": "downloads\\2023\\2023_0284.pdf", "extraction_method": "pdfminer", "checksum": "sha256:02c1a54113e4146bf08f47e20d3abe4a8298a95acbe5cf4c1edc8bec30c774a8", "cross_refs": []}
{"doc_id": "si-2023-0284-reg-7", "parent_doc_id": "si-2023-0284", "section_id": "reg-7", "section_label": "Regulation 7.", "si_number": "S.I. No. 284 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "7. Regulation 8(4) (inserted by Regulation 5 of the Regulations of 2020) of", "text_raw": "7. Regulation 8(4) (inserted by Regulation 5 of the Regulations of 2020) of \nthe Principal Regulations is amended by substituting “Covid-19 situation” for \n“Covid-19 emergency” in each place it occurs.", "text_norm": "7 regulation 8(4) (inserted regulation 5 regulation 2020) principal regulation amended substituting covid-19 situation covid-19 emergency place occurs", "start_char": 3340, "end_char": 3544, "source_path": "downloads\\2023\\2023_0284.pdf", "extraction_method": "pdfminer", "checksum": "sha256:02c1a54113e4146bf08f47e20d3abe4a8298a95acbe5cf4c1edc8bec30c774a8", "cross_refs": []}
{"doc_id": "si-2023-0284-reg-8", "parent_doc_id": "si-2023-0284", "section_id": "reg-8", "section_label": "Regulation 8.", "si_number": "S.I. No. 284 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "8. The Eighth Schedule (as amended by Regulation 3 of the Regulations of", "text_raw": "8. The Eighth Schedule (as amended by Regulation 3 of the Regulations of \n\n2023) to the Principal Regulations is amended— \n\n(a) \n\nin columns 4 and 5 of the entry for “Nuvaxovid dispersion for \ninjection COVID-19 Vaccine (recombinant, adjuvanted)”, by \nsubstituting “12 years” for “18 years” in each place it occurs, and \n\n(b) by inserting the following entry: \n\n“ \n\nMedicinal \nProduct \n\nRoute of \nadministratio\nn \n\nForm and \npresentation \nof product \nadministere\nd \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadministere\nd \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministrati\non \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nColumn 6 \n\nVidPrevtyn \nBeta \nsolution and \nemulsion \nfor \nemulsion \nfor injection \n\nCOVID-19 \nvaccine \n(recombina\nnt, \n\nSolution \nand \nemulsion \nfor \nemulsion \nfor \ninjection. \n\nThe antigen \nsolution is a \n\nAdministered \nintramuscular\nly only after \nmixing. \n\nIndicated as \na booster \nvaccine for \nactive \nimmunisati\non to \nprevent \nCOVID-19 \ncaused by \nSARSCoV-2 \n\nIn accordance \nwith relevant \nrecommendatio\nns or \nguidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \n\nAny suitable \nand \nappropriate \nplace, \nhaving \nregard to \npublic \nconvenience \nand the need \nto protect \nthe health \n\n \n \n \n \n \n\fand safety \nof the public \nand safely \nadminister \nthe product. \n\nMinister for \nHealth. \n\nVidPrevtyn \nBeta is \nadministered \nintramuscularly \nas a single dose \nof 0.5 mL \n\nvirus, in \nindividuals \n18 years of \nage and \nolder who \nhave \npreviously \nreceived an \nmRNA or \nadenoviral \nvector \nCOVID-19 \nvaccine. \n\n4 [284] \n\nadjuvanted)\n. \n\ncolourless, \nclear liquid. \n\nThe \nadjuvant \nemulsion is \na whitish to \nyellowish \nhomogeneo\nus milky \nliquid. \n\nThese are \ntwo \nmultidose \nvials \n(antigen \nvial and \nadjuvant \nvial) that \nmust be \nmixed \nbefore use. \n\n”.", "text_norm": "8 eighth schedule (as amended regulation 3 regulation 2023) principal regulation amended-- (a) column 4 5 entry nuvaxovid dispersion injection covid-19 vaccine (recombinant adjuvanted) substituting 12 year 18 year place occurs (b) inserting following entry medicinal product route administratio n form presentation product administere indication medicinal product may administere dosage condition administration place administrati column 1 column 2 column 3 column 4 column 5 column 6 vidprevtyn beta solution emulsion emulsion injection covid-19 vaccine (recombina nt solution emulsion emulsion injection antigen solution administered intramuscular ly mixing indicated booster vaccine active immunisati prevent covid-19 caused sarscov-2 accordance relevant recommendatio n guideline issued national immunisation advisory committee accepted suitable appropriate place regard public convenience need protect health safety public safely administer product minister health vidprevtyn beta administered intramuscularly single dose 0.5 ml virus individual 18 year age older previously received mrna adenoviral vector covid-19 vaccine 4 284 adjuvanted)  colourless clear liquid adjuvant emulsion whitish yellowish homogeneo u milky liquid two multidose vial (antigen vial adjuvant vial) must mixed use", "start_char": 3544, "end_char": 5410, "source_path": "downloads\\2023\\2023_0284.pdf", "extraction_method": "pdfminer", "checksum": "sha256:02c1a54113e4146bf08f47e20d3abe4a8298a95acbe5cf4c1edc8bec30c774a8", "cross_refs": []}
{"doc_id": "si-2023-0284-reg-9", "parent_doc_id": "si-2023-0284", "section_id": "reg-9", "section_label": "Regulation 9.", "si_number": "S.I. No. 284 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "9. The Twelfth Schedule (as amended by Regulation 4 of the Regulations", "text_raw": "9. The Twelfth Schedule (as amended by Regulation 4 of the Regulations \n\nof 2023) to the Principal Regulations is amended— \n\n(a) \n\nin columns 4 and 5 of the entry for “Nuvaxovid dispersion for \ninjection COVID-19 Vaccine (recombinant, adjuvanted)”, by \nsubstituting “12 years” for “18 years” in each place it occurs, and \n\n(b) by inserting the following entry: \n\n“ \n\nMedicinal \nProduct \n\nForm and \npresentation of \nproduct \nadministered \n\nRoute of \nadministration \n\nDosage and \nconditions of \nadministration \n\nIndication for \nwhich the \nmedicinal \nproduct may \nbe \nadministered \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nVidPrevtyn \nBeta solution \nand emulsion \nfor emulsion \nfor injection \n\nCOVID-19 \nvaccine \n(recombinant, \nadjuvanted). \n\nSolution and \nemulsion for \nemulsion for \ninjection. \n\nAdministered \nintramuscularly \nonly after \nmixing. \n\nThe antigen \nsolution is a \ncolourless, \nclear liquid. \n\nIndicated as a \nbooster \nvaccine for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV-2 \nvirus, in \nindividuals 18 \nyears of age \n\nIn accordance \nwith relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \n\n \n \n \n \n \n \n \n \n\f[284] 5 \n\nand older who \nhave \npreviously \nreceived an \nmRNA or \nadenoviral \nvector \nCOVID-19 \nvaccine. \n\nMinister for \nHealth. \n\nVidPrevtyn Beta \nis administered \nintramuscularly \nas a single dose \nof 0.5 mL \n\nThe adjuvant \nemulsion is a \nwhitish to \nyellowish \nhomogeneous \nmilky liquid. \n\nThese are two \nmultidose vials \n(antigen vial \nand adjuvant \nvial) that must \nbe mixed \nbefore use. \n\n”. \n\nGIVEN under my Official Seal, \n\n1 June, 2023. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f6 [284]", "text_norm": "9 twelfth schedule (as amended regulation 4 regulation 2023) principal regulation amended-- (a) column 4 5 entry nuvaxovid dispersion injection covid-19 vaccine (recombinant adjuvanted) substituting 12 year 18 year place occurs (b) inserting following entry medicinal product form presentation product administered route administration dosage condition administration indication medicinal product may administered column 1 column 2 column 3 column 4 column 5 vidprevtyn beta solution emulsion emulsion injection covid-19 vaccine (recombinant adjuvanted) solution emulsion emulsion injection administered intramuscularly mixing antigen solution colourless clear liquid indicated booster vaccine active immunisation prevent covid-19 caused sars-cov-2 virus individual 18 year age accordance relevant recommendation guideline issued national immunisation advisory committee accepted 284 5 older previously received mrna adenoviral vector covid-19 vaccine minister health vidprevtyn beta administered intramuscularly single dose 0.5 ml adjuvant emulsion whitish yellowish homogeneous milky liquid two multidose vial (antigen vial adjuvant vial) must mixed use  given official seal 1 june 2023 stephen donnelly minister health 6 284", "start_char": 5410, "end_char": 7164, "source_path": "downloads\\2023\\2023_0284.pdf", "extraction_method": "pdfminer", "checksum": "sha256:02c1a54113e4146bf08f47e20d3abe4a8298a95acbe5cf4c1edc8bec30c774a8", "cross_refs": []}
{"doc_id": "si-2023-0284-explanatory-note", "parent_doc_id": "si-2023-0284", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 284 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to (1) remove references to the “Covid-19 \nemergency”, (2) change the age limit in the relevant Schedules in respect of the \nCovid-19 vaccine Nuvaxovid and (3) update the relevant schedules in relation to \nthe COVID-19 vaccines to include the VidPrevtyn Beta vaccine. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 4) Regulations 2023. \n\n \n \n \n \n \n \n \n\f[284] 7 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-492) 75. 5/23. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation (1) remove reference covid-19 emergency (2) change age limit relevant schedule respect covid-19 vaccine nuvaxovid (3) update relevant schedule relation covid-19 vaccine include vidprevtyn beta vaccine regulation may cited medicinal product (prescription control supply) (amendment) (no 4) regulation 2023 284 7 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-492) 75 5 23 propylon", "start_char": 7164, "end_char": 8333, "source_path": "downloads\\2023\\2023_0284.pdf", "extraction_method": "pdfminer", "checksum": "sha256:02c1a54113e4146bf08f47e20d3abe4a8298a95acbe5cf4c1edc8bec30c774a8", "cross_refs": []}
